Welcome to our dedicated page for Corbus Pharmaceuticals Holdings SEC filings (Ticker: CRBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Corbus Pharmaceuticals Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Corbus Pharmaceuticals Holdings's regulatory disclosures and financial reporting.
Corbus Pharmaceuticals Holdings, Inc. granted its Chief Medical Officer, Nicacio Leonardo Viana, new equity awards on August 16, 2026. He received 191,676 stock options to buy common stock at an exercise price of $10.09 per share, expiring on August 16, 2036. Under the company’s 2026 Inducement Award Plan, 25% of this option vests on August 3, 2027, with the remaining 75% vesting in equal monthly installments over 36 months starting September 3, 2027. He was also granted 58,333 restricted stock units (RSUs), settling in common shares, vesting 25% on each of the first four anniversaries beginning August 16, 2027, with specified prorated vesting and forfeiture terms if his service is terminated without cause after the first vesting date.
Citadel-affiliated entities and Kenneth Griffin report their equity position in Corbus Pharmaceuticals Holdings, Inc. The group reports beneficial ownership of 206,354 Shares of common stock, representing 1.1% of the outstanding Shares, based on 18,527,795 Shares outstanding as of May 8, 2026 as cited from Corbus’s Form 10-Q. Certain Citadel entities report 0 Shares and 0.0% ownership. Voting and dispositive authority over the 206,354 Shares is reported as shared among Citadel Securities LLC, Citadel Securities Group LP, Citadel Securities GP LLC, and Mr. Griffin, with no sole voting or dispositive power reported.
Corbus Pharmaceuticals Holdings, Inc. Chief Business Officer Nishant C Saxena purchased 2,600 shares of common stock on 2026-08-11 at an average price of $9.6294 per share in a direct open-market or private transaction. Following this trade, his direct holdings total 77,900 shares, which the footnote states include 58,300 unvested RSUs subject to a vesting schedule. The filing indicates the transaction was not made pursuant to a Rule 10b5-1 trading plan.
Corbus Pharmaceuticals Holdings, Inc. director and Chief Executive Officer Yuval Cohen reported selling 17,000 shares of common stock on August 7, 2026 at a weighted average price of $10.0821 per share. The sale was effected under a Rule 10b5-1 trading plan adopted on March 11, 2026. Following this transaction, Cohen holds 157,316 shares directly, including 138,049 unvested RSUs subject to vesting schedules.
Corbus Pharmaceuticals Holdings, Inc. Chief Financial Officer Sean F. Moran reported a sale of 12,000 shares of common stock on August 7, 2026. The shares were sold at a weighted average price of $10.0809 per share under a Rule 10b5-1 trading plan adopted on March 11, 2026. Following this transaction, Moran holds 84,694 shares directly, including 68,795 unvested RSUs that remain subject to their vesting schedules.
Corbus Pharmaceuticals Holdings, Inc. is establishing an at-the-market offering of its common stock under a shelf registration, allowing sales of up to $127,500,000 of shares from time to time through Jefferies LLC as sales agent. Jefferies may sell shares on Nasdaq under mutually agreed placement notices and will receive a 3% commission on gross proceeds, being deemed an underwriter for these transactions.
Assuming sales at $9.40 per share, the company illustrates issuance of 13,563,829 shares, which, together with prior sales, would increase common shares outstanding from 18,671,498 as of June 30, 2026 to up to 32,974,034. Pro forma as adjusted net tangible book value would rise to $228.7 million, or $6.94 per share, implying dilution of $2.46 per share to new investors relative to the assumed offering price. Corbus plans to use net proceeds primarily to advance its clinical pipeline, including CRB-701 in oncology and CRB-913 in obesity, and for general corporate purposes such as pre-clinical programs, working capital, potential acquisitions or investments, debt reduction and capital expenditures. The company highlights risks of share price volatility, potential dilution from existing equity awards and warrants, and uncertainty about the timing, pricing and total number of shares ultimately sold under the program.
An affiliate of CRBP has filed notice of intent to sell up to 12,000 shares of common stock through broker Stifel Nicolaus & Company Inc. on or after 08/07/2026 on the Nasdaq market, with an indicated aggregate market value of $120,971.00.
The shares relate to equity compensation in the form of Restricted Stock Units, including 7,317 shares tied to RSUs dated 02/12/2026 and 4,683 shares tied to RSUs dated 01/31/2026.
A shareholder of CRBP has notified an intention to sell 17,000 shares of common stock through Stifel Nicolaus & Company Inc. The proposed sale has an indicated value of $171,396.00 and is listed for trading on Nasdaq with a proposed sale date of 08/07/2026.
The planned sale is supported by equity awards consisting of restricted stock units granted as equity compensation, including 9,210 units dated 02/12/2025 and 7,790 units dated 01/31/2026.
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company developing therapies in oncology and obesity, led by CRB-701, a Nectin-4–targeting antibody drug conjugate, and CRB-913, a peripherally restricted CB1 inverse agonist for obesity. For the six months ended June 30, 2026, it reported a net loss of approximately $58.0 million, compared with $34.6 million a year earlier, as research and development expenses rose to $51.0 million, driven by a $10.0 million CRB-701 development milestone to CSPC and higher clinical spending on both CRB-701 and CRB-913.
Cash, cash equivalents and investments totaled approximately $117.9 million at June 30, 2026, and management expects this to fund operations for at least twelve months from the report issuance. The company raised about $9.1 million in Q2 2026 through at-the-market stock sales, with an additional $6.7 million raised after quarter-end. CRB-913 showed a mean 2.9% placebo-adjusted weight loss by Day 14 in an obese Phase 1a cohort, and a 240-patient Phase 1b study completed last visits in August 2026, with data expected in September 2026. CRB-701 has fast track designations in cervical cancer and HNSCC, with a registrational 2L OPSCC study (TEMPO-1) expected to begin enrollment in September 2026; the CRB-601 program has been deprioritized.
Corbus Pharmaceuticals Holdings reported second-quarter 2026 results and corporate updates, highlighting progress in its oncology and obesity pipeline. The company obtained FDA clearance to proceed with TEMPO-1, a registrational Phase 3 study of CRB-701 in second-line oropharyngeal cancer, and plans to begin enrollment in September 2026. It also completed last patient last visit in the 240-patient CANYON-1 Phase 1b trial of CRB-913 in obesity, with topline data expected in September 2026, and strengthened leadership with a new Chief Medical Officer, Chief Business Officer and Board member.
For the quarter ended June 30, 2026, Corbus recorded a net loss of approximately $35.0 million, or $1.81 per basic and diluted share, compared with a net loss of approximately $17.7 million, or $1.44 per share, a year earlier. Operating expenses rose to approximately $36.2 million from $19.2 million, driven largely by increased clinical development spending, including a $10.0 million milestone payment under the CRB-701 license. Cash, cash equivalents and investments totaled $117.9 million as of June 30, 2026, which Corbus expects will fund operations into 2028 based on current plans.